---
{"dg-publish":true,"permalink":"/jethro-s-working-notes/direct-acting-antivirals-for-hcv/","dgPassFrontmatter":true}
---


# Direct-acting antivirals for HCV

Created: November 15, 2022 10:22 AM
Tags: GIS, Medicine, Pharmacology
Updated: November 24, 2022 5:05 PM

### Direct-acting antivirals for HCV

Direct-acting antivirals are a new class of drug used in the treatment of chronic hepatitis C, and can greatly shorten the duration of treatment.

### **********************************NS3/4A inhibitors**********************************

- **********************************************************Examples of NS3/4A inhibitors**********************************************************
    
    Simeprevir, Boceprevir, Telaprevir
    
    ![[Untitled\|Untitled]]
    
- ************************************************MOA of NS3/4A inhibitors************************************************
    
    NS3/4A inhibitor inhibits the protease and its confactor, thus prevents cleavage of polyprotein into functional proteins, thus inhibiting the viral cycle.
    

### NS5A inhibitors

- ******************************************************Examples of NS5A inhibitors******************************************************
    
    Ledipasvir, Ombitasvir
    
    ![[Untitled\|Untitled]]
    
- ********************************************MOA of NS5A inhibitors********************************************
    
    NS5A inhibitors inhibit NS5A that is required for viral replication and assembly.
    

### NS5B inhibitors

- ******************************************************Examples of NS5B inhibitors******************************************************
    
    Sofobuvir - NS5B nucleoside inhibitor
    
    Dasabuvir - NS5B non-nucleoside inhibitor
    
- ********************************************MOA of NS5B inhibitors********************************************
    
    NS5B inhibitors inhibit RNA-dependent RNA polymerase, thus inhibiting RNA replication and the viral cycle.
    

### NS3/4A inhibitors, NS5A inhibitors, NS5B NI and NS5N differ in terms of genotypical coverage, potency and barriers to resistance

![[Untitled\|Untitled]]

![[Untitled\|Untitled]]